ReviewAnnals of translational medicine2021
Non-alcoholic fatty liver diseases: current challenges and future directions.
Review in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of artificial intelligence models for imaging detection of hepatic steatosis through systematic review and meta analysis.Scientific reports · 2025Pooled it
- Exercise and dietary interventions in the regulation of hepatic mitophagy and liver recovery (Review).Biomedical reports · 2026Review
- Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C.Viruses · 2026Article
- METTL7A is a key regulator of hepatic lipid metabolism and nonalcoholic fatty liver disease progression.Scientific reports · 2026Article
- Liver-specific SLC13A3 modulation alleviates MASLD by regulating NADMolecular and cellular biochemistry · 2026Article
- Senescent hepatic stellate cells drive inflammation and disease progression in MASH (Review).Experimental and therapeutic medicine · 2026Review
- Artificial intelligence‑based quantitative analysis of hepatic fibrosis in carbon tetrachloride-induced mouse model of metabolic dysfunction-associated steatohepatitis.Toxicological research · 2026Article
- Nonalcoholic Fatty Liver Disease Status and Its Associated Factors Among Patients With Type 2 Diabetes Mellitus in Adama Hospital Medical College, South Eastern Ethiopia: A Cross-Sectional Study.Health science reports · 2026Article
- The Niemann-Pick C1 Protein of Patients with Hepatocellular Carcinoma Is Associated with Survival Time in Males and Tumor Size in Females.Biomedicines · 2025Article
- Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discover oncology · 2025Review
- The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different?Frontiers in endocrinology · 2025Review
- Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.Biomedicines · 2024Review
- Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma.Journal of translational medicine · 2024Article
- Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review.Cureus · 2023Review
- Interleukin-13 (IL-13)-A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis.International journal of molecular sciences · 2023Review
- LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity.International journal of molecular sciences · 2023Article
- [Nonalcoholic fatty liver disease : Hepatic manifestations of metabolic syndrome].Innere Medizin (Heidelberg, Germany) · 2023Review
- Article
- Gentiopicroside improves high-fat diet-induced NAFLD in association with modulation of host serum metabolome and gut microbiome in mice.Frontiers in microbiology · 2023Article
- Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects.Journal of clinical and translational hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver diseases (NAFLD) is rapidly becoming the most common cause of chronic liver disease in Western Countries, and a similar trend is expected in Eastern Countries within the next years. This review focusses on the definition of NAFLD and NASH, possible screening mechanisms and the question who should be screened. Still there is a need for non-invasive diagnostic tools and biomarkers for NASH that can quickly and easily diagnose the severity of NAFLD, monitor liver changes, and identify high risk patients. In addition, treatment strategies are discussed as well as the clientele, who should be treated. There are currently no drugs approved for NAFLD. Successful clinical studies with e.g., obeticholic acid and new substances (e.g., cenicriviroc with anti-inflammatory activity) have already been published. If weight-reducing diets and a change in lifestyle fail in the case of severe obesity, bariatric surgery (e.g., gastric bypass or stomach reduction) should be considered. In the case of manifest type 2 diabetes, metformin can be used as an oral antidiabetic of first choice, and GLP-1 agonists have shown beneficial effects on NAFLD. However, up to now the prevention of overweight and lack of exercise targets the most important risk factors. This review aims to identify therapy relevant risk factors, management strategies, and open questions concerning NAFLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.